| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $597K | -43.9% | -38.6% |
| SG&A Expense | $1.9M | -40.7% | -36.5% |
| Operating Income | -$2.5M | +42.5% | +37.9% |
| Pre-tax Income | -$4.5M | +31.7% | +26.5% |
| Net Income | -$4.5M | +31.7% | +26.5% |
| EPS (Basic) | -$0.39 | +35.0% | -143.8% |
| EPS (Diluted) | -$0.39 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $5.9M | -29.8% | +1003.7% |
| Current Assets | $7.4M | -27.8% | +212.6% |
| Total Assets | $8.7M | -25.1% | +118.1% |
| Current Liabilities | $8.2M | -9.9% | -23.3% |
| Total Liabilities | $28.6M | +4.0% | -20.7% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$12.6M | — | — |
| Capital Expenditures | $4K | — | — |
| Investing Cash Flow | -$4K | — | — |
| Financing Cash Flow | $18.5M | — | — |
| Free Cash Flow | -$12.6M | — | — |
| +35.0% |
| -143.8% |
| -$19.9M |
| -25.4% |
| +38.1% |